Nasdaq

Seqirus Publishes New Real-World Evidence (RWE) on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Vaccines

SUMMIT, N.J., Sept. 21, 2020 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) that demonstrated an MF59® adjuvanted, ...
News Medical

COVID booster vaccination more effective relative to 2-dose series

In a recent study published on the medRxiv* preprint server, researchers have revealed that a booster dose of a messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine is ...
The New England Journal of Medicine

Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age

Quadrivalent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard-dose egg-based vaccines, and the recombinant formulation is not susceptible to antigenic ...
Nasdaq

Seqirus Presents New Real-World Evidence Demonstrating Effectiveness of Cell-Based and Adjuvanted Seasonal Influenza Vaccines at IDWeek 2021

SUMMIT, N.J., Sept. 29, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced data supporting the effectiveness of both ...
Business Insider

Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020

SUMMIT, N.J., Oct. 21, 2020 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) on the effectiveness of an MF59 ®-adjuvanted, trivalent ...